The Application of Biopsy Density in Transperineal Templated-Guided Biopsy Patients With PI-RADS<3

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Jun 27

PMID 35756615

Authors

Hai Zhu

Xue-Fei Ding

Sheng-Ming Lu

Ning Ding

Shi-Yi Pi

Zhen Liu

Qin Xiao

Liang-Yong Zhu

Yang Luan

Yue-Xing Han

Hao-Peng Chen

Zhong Liu

Affiliations

Soon will be listed here.

Abstract

Background: In patients with multiparameter magnetic resonance imaging (mpMRI) low-possibility but highly clinical suspicion of prostate cancer, the biopsy core is unclear. Our study aims to introduce the biopsy density (BD; the ratio of biopsy cores to prostate volume) and investigates the BD-predictive value of prostate cancer and clinically significant prostate cancer (csPCa) in PI-RADS<3 patients.

Methods: Patients underwent transperineal template-guided prostate biopsy from 2012 to 2022. The inclusion criteria were PI-RADS<3 with a positive digital rectal examination or persistent PSA abnormalities. BD was defined as the ratio of the biopsy core to the prostate volume. Clinical data were collected, and we grouped the patients according to pathology results. Kruskal-Wallis test and chi-square test were used in measurement and enumeration data, respectively. Logistics regression was used to choose the factor associated with positive biospy and csPCa. The receiver operating characteristic (ROC) curve was used to evaluate the ability to predict csPCa.

Results: A total of 115 patients were included in our study. Biopsy was positive in 14 of 115 and the International Society of Urological Pathology grade groups 2-5 were in 7 of all the PCa patients. The BD was 0.38 (0.24-0.63) needles per milliliter. Binary logistics analysis suggested that PSAD and BD were correlated with positive biopsy. Meanwhile, BD and PSAD were associated with csPCa. The ROC curve illustrated that BD was a good parameter to predict csPCa (AUC=0.80, 95% CI: 0.69-0.91, p<0.05). The biopsy density combined with PSAD increased the prediction of csPCa (AUC=0.90, 95% CI: 0.85-0.97, p<0.05). The cut-off value of the BD was 0.42 according to the Youden index.

Conclusion: In PI-RADS<3 patients, BD and PSAD are related to csPCa. A biopsy density of more than 0.42 needles per millimeter can increase the csPCa detection rate, which should be considered as an alternative biopsy method when we perform prostate biopsy in patients with PI-RADS<3.

Citing Articles

Magnetic Resonance Imaging, Clinical, and Biopsy Findings in Suspected Prostate Cancer: A Systematic Review and Meta-Analysis.

Haj-Mirzaian A, Burk K, Lacson R, Glazer D, Saini S, Kibel A JAMA Netw Open. 2024; 7(3):e244258.

PMID: 38551559 PMC: 10980971. DOI: 10.1001/jamanetworkopen.2024.4258.

References

Wang B, Chen C, Zheng R, Hu J, Ou Y . Comparison of cancer detection between 18- and 12-core prostate biopsy in Asian patients with prostate-specific antigen levels of 4-20 ng/mL. J Chin Med Assoc. 2018; 81(12):1044-1051. DOI: 10.1016/j.jcma.2018.06.003. View

Maggi M, Panebianco V, Mosca A, Salciccia S, Gentilucci A, Di Pierro G . Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2019; 6(3):463-478. DOI: 10.1016/j.euf.2019.06.014. View

Busetto G, Giovannone R, Antonini G, Rossi A, Del Giudice F, Tricarico S . Short-term pretreatment with a dual 5α-reductase inhibitor before bipolar transurethral resection of the prostate (B-TURP): evaluation of prostate vascularity and decreased surgical blood loss in large prostates. BJU Int. 2014; 116(1):117-23. DOI: 10.1111/bju.12917. View

Johnson D, Raman S, Mirak S, Kwan L, Bajgiran A, Hsu W . Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2018; 75(5):712-720. DOI: 10.1016/j.eururo.2018.11.031. View

Bostwick D, COONER W, Denis L, Jones G, Scardino P, Murphy G . The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992; 70(1 Suppl):291-301. DOI: 10.1002/1097-0142(19920701)70:1+<291::aid-cncr2820701317>3.0.co;2-4. View

Al-Khalil S, Boothe D, Durdin T, Sunkara S, Watkins P, Yang S . Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review. Int Urol Nephrol. 2015; 48(1):91-7. DOI: 10.1007/s11255-015-1146-2. View

He B, Chen R, Shi Z, Xiao G, Li H, Lin H . Trans-Perineal Template-Guided Mapping Biopsy vs. Freehand Trans-Perineal Biopsy in Chinese Patients With PSA < 20 ng/ml: Similar Cancer Detection Rate but Different Lesion Detection Rate. Front Oncol. 2019; 9:758. PMC: 6696794. DOI: 10.3389/fonc.2019.00758. View

Epstein J, Egevad L, Amin M, Delahunt B, Srigley J, Humphrey P . The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2015; 40(2):244-52. DOI: 10.1097/PAS.0000000000000530. View

Stone N, Crawford E, Skouteris V, Arangua P, Metsinis P, Lucia M . The Ratio of the Number of Biopsy Specimens to Prostate Volume (Biopsy Density) Greater Than 1.5 Improves the Prostate Cancer Detection Rate in Men Undergoing Transperineal Biopsy of the Prostate. J Urol. 2019; 202(2):264-271. DOI: 10.1097/JU.0000000000000204. View

10.

van Houdt P, Ghobadi G, Schoots I, Heijmink S, De Jong J, van der Poel H . Histopathological Features of MRI-Invisible Regions of Prostate Cancer Lesions. J Magn Reson Imaging. 2019; 51(4):1235-1246. DOI: 10.1002/jmri.26933. View

11.

Ficarra V, Novella G, Novara G, Galfano A, Pea M, Martignoni G . The potential impact of prostate volume in the planning of optimal number of cores in the systematic transperineal prostate biopsy. Eur Urol. 2005; 48(6):932-7. DOI: 10.1016/j.eururo.2005.08.008. View

12.

Anastay V, Gondran-Tellier B, McManus R, Delonca R, Akiki A, Gaillet S . Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary?. Abdom Radiol (NY). 2020; 45(12):4160-4165. DOI: 10.1007/s00261-020-02728-8. View

13.

Nakai Y, Tanaka N, Anai S, Miyake M, Hori S, Tatsumi Y . Transperineal template-guided saturation biopsy aimed at sampling one core for each milliliter of prostate volume: 103 cases requiring repeat prostate biopsy. BMC Urol. 2017; 17(1):28. PMC: 5382378. DOI: 10.1186/s12894-017-0219-1. View

14.

Maggi M, Del Giudice F, Falagario U, Cocci A, Russo G, DI Mauro M . SelectMDx and Multiparametric Magnetic Resonance Imaging of the Prostate for Men Undergoing Primary Prostate Biopsy: A Prospective Assessment in a Multi-Institutional Study. Cancers (Basel). 2021; 13(9). PMC: 8122883. DOI: 10.3390/cancers13092047. View

15.

Leitao T, Alfarelos J, Rodrigues T, Pereira E Silva R, Garcia R, Martinho D . A Prospective Randomized Trial Comparing the Vienna Nomogram and a Ten-Core Prostate Biopsy Protocol: Effect on Cancer Detection Rate. Clin Genitourin Cancer. 2016; 15(1):117-121. DOI: 10.1016/j.clgc.2016.06.003. View

16.

Meier-Schroers M, Kukuk G, Wolter K, Decker G, Fischer S, Marx C . Differentiation of prostatitis and prostate cancer using the Prostate Imaging-Reporting and Data System (PI-RADS). Eur J Radiol. 2016; 85(7):1304-11. DOI: 10.1016/j.ejrad.2016.04.014. View

17.

Matoso A, Epstein J . Defining clinically significant prostate cancer on the basis of pathological findings. Histopathology. 2018; 74(1):135-145. DOI: 10.1111/his.13712. View

18.

Ahmed H, El-Shater Bosaily A, Brown L, Gabe R, Kaplan R, Parmar M . Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017; 389(10071):815-822. DOI: 10.1016/S0140-6736(16)32401-1. View

19.

Tataru O, Vartolomei M, Rassweiler J, Virgil O, Lucarelli G, Porpiglia F . Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives. Diagnostics (Basel). 2021; 11(2). PMC: 7924061. DOI: 10.3390/diagnostics11020354. View

20.

Mortezavi A, Marzendorfer O, Donati O, Rizzi G, Rupp N, Wettstein M . Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer. J Urol. 2018; 200(2):309-318. DOI: 10.1016/j.juro.2018.02.067. View